Felipe
Prosper Cardoso
Consultor Médico
Hospital Universitario Marqués de Valdecilla
Santander, EspañaPublications in collaboration with researchers from Hospital Universitario Marqués de Valdecilla (18)
2023
-
Integrated flow cytometry and sequencing to reconstruct evolutionary patterns from dysplasia to acute myeloid leukemia
Blood Advances, Vol. 7, Núm. 1, pp. 167-173
-
Phase I study of plitidepsin in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma
Cancer Medicine, Vol. 12, Núm. 4, pp. 3999-4009
2022
-
Circulating Tumor and Immune Cells for Minimally Invasive Risk Stratification of Smoldering Multiple Myeloma
Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 28, Núm. 21, pp. 4771-4781
2021
-
Tumor cells in light-chain amyloidosis and myeloma show distinct transcriptional rewiring of normal plasma cell development
Blood, Vol. 138, Núm. 17, pp. 1583-1589
2019
-
Dual Targeting of Histone Methyltransferase G9a and DNA-Methyltransferase 1 for the Treatment of Experimental Hepatocellular Carcinoma
Hepatology, Vol. 69, Núm. 2, pp. 587-603
2018
-
Richter transformation driven by Epstein–Barr virus reactivation during therapy-related immunosuppression in chronic lymphocytic leukaemia
Journal of Pathology, Vol. 245, Núm. 1, pp. 61-73
2016
2012
-
Expression of MALT1 oncogene in hematopoietic stem/progenitor cells recapitulates the pathogenesis of human lymphoma in mice
Proceedings of the National Academy of Sciences of the United States of America, Vol. 109, Núm. 26, pp. 10534-10539
-
High-throughput sequencing analysis of the chromosome 7q32 deletion reveals IRF5 as a potential tumour suppressor in splenic marginal-zone lymphoma
British Journal of Haematology, Vol. 158, Núm. 6, pp. 712-726
2006
2004
-
Imatinib Inhibits Proliferation of Ewing Tumor Cells Mediated by the Stem Cell Factor/KIT Receptor Pathway, and Sensitizes Cells to Vincristine and Doxorubicin-Induced Apoptosis
Clinical Cancer Research, Vol. 10, Núm. 2, pp. 751-761
-
NALP1 is a transcriptional target for cAMP-response-element-binding protein (CREB) in myeloid leukaemia cells
Biochemical Journal, Vol. 384, Núm. 2, pp. 281-286
2003
-
Lack of Bcr-Abl point mutations in chronic myeloid leukemia patients in chronic phase before imatinib treatment is not predictive of response
Haematologica, Vol. 88, Núm. 12, pp. 1425-1426
2002
-
Induction of Nod2 in myelomonocytic and intestinal epithelial cells via nuclear factor-κB activation
Journal of Biological Chemistry, Vol. 277, Núm. 44, pp. 41701-41705
-
Nuclear factor κ B is activated in myelodysplastic bone marrow cells
Haematologica, Vol. 87, Núm. 9, pp. 1005-1006
2001
-
Antiapoptotic protein Bcl-xL is up-regulated during megakaryocytic differentiation of CD34+ progenitors but is absent from senescent megakaryocytes
Experimental Hematology, Vol. 29, Núm. 6, pp. 728-735
2000
-
Blockade of the Bcr-Abl kinase activity induces apoptosis of chronic myelogenous leukemia cells by suppressing signal transducer and activator of transcription 5-dependent expression of Bcl-x(L)
Journal of Experimental Medicine, Vol. 191, Núm. 6, pp. 977-984
1999
-
Erythropoietin can induce the expression of Bcl-x(L) through Stat5 in erythropoietin-dependent progenitor cell lines
Journal of Biological Chemistry, Vol. 274, Núm. 32, pp. 22165-22169